Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban

Heart

Volumn 102, Issue 13, 2016, Pages 1036-1043

  Breithardt, Günter ^a   Baumgartner, Helmut ^a   Berkowitz, Scott D ^b   Hellkamp, Anne S ^c   Piccini, Jonathan P ^c   Lokhnygina, Yuliya ^c   Halperin, Jonathan L ^d   Singer, Daniel E ^e   Hankey, Graeme J ^f   Hacke, Werner ^g   Becker, Richard C ^h   Nessel, Christopher C ⁱ   Mahaffey, Kenneth W ^j   Califf, Robert M ^k   Fox, Keith A A ^l   Patel, Manesh R ^c  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b BAYER CORPORATION   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

ⁱ JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF EDINBURGH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT;

AGED; AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; NONVALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIGNIFICANT VALVE DISEASE; SYSTEMIC EMBOLISM; TREATMENT OUTCOME; VALVULAR HEART DISEASE; AORTIC REGURGITATION; AORTIC VALVE STENOSIS; COMPARATIVE STUDY; COMPLICATION; DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; STROKE; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; ATRIAL FIBRILLATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MITRAL VALVE INSUFFICIENCY; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84959432866     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-308120     Document Type: Article

References (46)

1. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010; 159: 340-7.e1.
2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91.
3. Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014; 35: 3377-85.
4. Hohnloser SH, Lopes RD. Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention. Eur Heart J. 2014; 35: 3323-5.
5. Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2015; 132: 624-32.
6. Ezekowitz MD, Parise H, Nagarakanti R, et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial [Abstract]. J Am Coll Cardiol. 2014; 63: A325.
7. Breithardt G, Baumgartner H, Berkowitz SD, et al. Patients with native aortic stenosis represent a high-risk subgroup in nonvalvular atrial fibrillation-results from ROCKET AF[Abstract 5835]. Eur Heart J. 2014; 35(Abstract Supplement): 1033.
8. Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999; 341: 142-7.
9. Greve AM, Dalsgaard M, Bang CN, et al. Stroke in patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. Stroke. 2014; 45: 1939-46.
10. Baskett RJ, Exner DV, Hirsch GM, et al. Mitral insufficiency and morbidity and mortality in left ventricular dysfunction. Can J Cardiol. 2007; 23: 797-800. doi: 10. 1016/S0828-282X(07)70830-9
11. Koelling TM, Aaronson KD, Cody RJ, et al. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J. 2002; 144: 524-9.
12. Robbins JD, Maniar PB, Cotts W, et al. Prevalence and severity of mitral regurgitation in chronic systolic heart failure. Am J Cardiol. 2003; 91: 360-2.
13. Shimada S. A 13-year follow-up study of rheumatic valvular diseases. Jpn Circ J. 1986; 50: 1304-8.
14. Bonow RO, Carabello B, de Leon AC Jr, et al. ACC/AHA guidelines for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). Circulation. 1998; 98: 1949-84.
15. Salem DN, Levine HJ, Pauker SG, et al. Antithrombotic therapy in valvular heart disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 1998; 114: e590S-601S.
16. [No authors listed]. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol. 1986; 43: 71-84.
17. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012; 33: 2451-96.
18. Petty GW, Khandheria BK, Whisnant JP, et al. Predictors of cerebrovascular events and death among patients with valvular heart disease: a population-based study. Stroke. 2000; 31: 2628-35.
19. Davidsen B, Egeblad H, Pietersen A. Thromboembolism in patients with advanced mitral valve prolapse. J Intern Med. 1989; 226: 433-6.
20. Davison G, Greenland P. Predictors of left atrial thrombus in mitral valve disease. J Gen Intern Med. 1991; 6: 108-12.
21. Movsowitz C, Movsowitz HD, Jacobs LE, et al. Significant mitral regurgitation is protective against left atrial spontaneous echo contrast and thrombus as assessed by transesophageal echocardiography. J Am Soc Echocardiogr. 1993; 6: 107-14.
22. Blackshear JL, Pearce LA, Asinger RW, et al. Mitral regurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Am J Cardiol. 1993; 72: 840-3.
23. Karatasakis GT, Gotsis AC, Cokkinos DV. Influence of mitral regurgitation on left atrial thrombus and spontaneous echocardiographic contrast in patients with rheumatic mitral valve disease. Am J Cardiol. 1995; 76: 279-81.
24. Miyasaka Y, Tsuji H, Tokunaga S, et al. Mild mitral regurgitation was associated with increased prevalence of thromboembolic events in patients with nonrheumatic atrial fibrillation. Int J Cardiol. 2000; 72: 229-33.
25. Nair CK, Aronow WS, Shen X, et al. Effect of mitral regurgitation on cerebrovascular accidents in patients with atrial fibrillation and left atrial thrombus. Clin Cardiol. 2009; 32: E7-E10.
26. Tse HF, Lau CP, Cheng G. Relation between mitral regurgitation and platelet activation. J Am Coll Cardiol. 1997; 30: 1813-18.
27. Tamayo S, Peacock WF, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27, 467 patients taking rivaroxaban. Clin Cardiol. 2015; 38: 63-8.
28. Varol E, Arslan A, Yucel H, et al. Increased mean platelet volume in patients with aortic stenosis. Clin Appl Thromb Hemost. 2011; 17: E17-20.
29. Sucu M, Davutoglu V, Sari I, et al. Relationship between platelet indices and aortic valve sclerosis. Clin Appl Thromb Hemost. 2010; 16: 563-7.
30. Dimitrow PP, Hlawaty M, Undas A, et al. Effect of aortic valve stenosis on haemostasis is independent from vascular atherosclerotic burden. Atherosclerosis. 2009; 204: e103-8.
31. Chirkov YY, Mishra K, Chandy S, et al. Loss of anti-Aggregatory effects of aortic valve tissue in patients with aortic stenosis. J Heart Valve Dis. 2006; 15: 28-33.
32. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003; 349: 343-9.
33. Lip GY, Lowe GD, Rumley A, et al. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995; 73: 527-33. doi: 10. 1136/hrt.73.6.527
34. Freestone B, Gustafsson F, Chong AY, et al. Influence of atrial fibrillation on plasma von Willebrand factor, soluble E-selectin, and N-Terminal pro B-Type natriuretic peptide levels in systolic heart failure. Chest. 2008; 133: 1203-8.
35. Gustafsson C, Blombäck M, Britton M, et al. Coagulation factors and the increased risk of stroke in non-valvular atrial fibrillation. Stroke. 1990; 21: 47-51.
36. Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-Adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke. 2000; 31: 828-33.
37. Heyde EC. Gastrointestinal bleeding in aortic stenosis. N Engl J Med. 1958; 259: 196.
38. Greenstein RJ, McElhinney AI, Reuben D, et al. Colonic vascular ectasias and aortic stenosis: coincidence or causal relationship? Am J Surg. 1986; 151: 347-51.
39. King RM, Pluth JR, Giuliani ER. The association of unexplained gastrointestinal bleeding with calcific aortic stenosis. Ann Thorac Surg. 1987; 44: 514-16.
40. Pate GE, Mulligan A. An epidemiological study of Heyde?s syndrome: an association between aortic stenosis and gastrointestinal bleeding. J Heart Valve Dis. 2004; 13: 713-6.
41. Warkentin TE, Moore JC, Morgan DG. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand?s disease the link? Lancet. 1992; 340: 35-7.
42. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994; 83: 2171-9.
43. Anderson RP, McGrath K, Street A. Reversal of aortic stenosis, bleeding gastrointestinal angiodysplasia, and von Willebrand syndrome by aortic valve replacement. Lancet. 1996; 347: 689-90.
44. Pareti FI, Lattuada A, Bressi C, et al. Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation. 2000; 102: 1290-5.
45. Thompson JL III, Schaff HV, Dearani JA, et al. Risk of recurrent gastrointestinal bleeding after aortic valve replacement in patients with Heyde syndrome. J Thoracic Cardiovasc Surg. 2012; 144: 112-16.
46. Loscalzo J. Basic implications of clinical observations: from clinical observation to mechanism-Heyde?s Syndrome. N Engl J Med. 2012; 367: 1954-6.